Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.
--------
Question: Context: Ten-year-old Chihiro (voice: Daveigh Chase in the 2002 English dub) and her parents (voices: Lauren Holly and Michael Chiklis) drive to their new home. Chihiro is whiny and unhappy about the move, especially when she notices that the bouquet her friend gave her as a good-bye gift is wilting. In sight of their new house, they take a wrong turn and follow a bumpy, decayed old road through the woods; Chihiro sees an odd old statue through the trees as they drive by. The road ends at a tunnel leading to an abandoned theme park. It gives Chihiro the creeps, but her parents persuade her to go in with them and look around.After wandering across a grassy landscape and a dry riverbed, they climb a stone staircase and come to a street lined with restaurants and shops. Most are deserted, but the aroma of cooking leads them to the one restaurant that's well stocked with food -- though it's mysteriously deserted. Mom and Dad are hungry and start eating, despite Chihiro's objections. The food is delicious, and Chihiro wanders away to explore while they eat. She finds a towering, ornate building that she recognizes as a bathhouse (a spa resort); there's a train track running under it. She meets a boy (voice: Jason Marsden) in traditional dress who is alarmed to see her; he tells her to leave and get back across the river before it gets dark. Chihiro runs back to her parents, but they're still eating -- and they've turned into pigs. Strange, dark, ghostly figures appear in all the shops and streets, frightening Chihiro and separating her from the pigs that were her parents. Chihiro runs back to the river, which was nearly dry when they came over but is now full and large, and she doesn't even recognize the buildings on the far side. As a riverboat approaches, she notices that her body has become transparent.The riverboat lands a big crowd of people in costume -- or maybe they're not people; at first they're only visible as paper masks. Chihiro thinks shes dreaming, but can't wake up. The boy who warned her away finds her and tells her she must eat some food from his world or she'll fade away. He assures her that she won't turn into a pig. She swallows the morsel he gives her and becomes solid, but finds that she's stuck to the ground until he recites an incantation to release her. A bird with a woman's head flies above them and he hides her, saying the bird is looking for her. They run through alleys and the pig barn to the big bathhouse, which is accessed by a bridge; the boy says she has to hold her breath as they cross the bridge or the spell that makes her invisible will be broken. Customers -- fantastically varied gods and spirits -- are crossing the bridge and being greeted by bathhouse staff. Chihiro makes it almost all the way across, but a frog (voice: Bob Bergen) that speaks to her companion (calling him Haku) startles her and she takes a breath. Luckily only the frog seems to see her, and Haku uses magic to encase it in a bubble to shut it up.Haku tells her to find Kamajii (voice: David Ogden Stiers), the boiler man, and make him give her a job; she must have a job to stay at the bathhouse, or else Yubaba (voice: Suzanne Pleshette), the old witch who rules the bathhouse, will turn her into an animal. And Haku says she has to stay if she wants to find and help her parents, who are still pigs, wherever they are. He knows her name and says he's known her since she was very small.Chihiro descends a steep, winding, rail-less wooden stairway in search of Kamajii and the boiler room. When she finds them, she sees a weird set-up in which the boiler is fed by creatures like spiders (delivering coal one lump at a time) and the machinery is controlled by a bearded, bald man 
 Question: what does the paper shikigami attack?

Answer: a dragon


Question: Context: Our previous work has shown that gene knockout of the sodium-glucose cotransporter SGLT2 modestly lowered blood glucose in streptozotocin-diabetic mice (BG; from 470 to 300 mg/dl) and prevented glomerular hyperfiltration but did not attenuate albuminuria or renal growth and inflammation. Here we determined effects of the SGLT2 inhibitor empagliflozin (300 mg/kg of diet for 15 wk; corresponding to 60-80 mgkg(-1)day(-1)) in type 1 diabetic Akita mice that, opposite to streptozotocin-diabetes, upregulate renal SGLT2 expression. Akita diabetes, empagliflozin, and Akita + empagliflozin similarly increased renal membrane SGLT2 expression (by 38-56%) and reduced the expression of SGLT1 (by 33-37%) vs. vehicle-treated wild-type controls (WT). The diabetes-induced changes in SGLT2/SGLT1 protein expression are expected to enhance the BG-lowering potential of SGLT2 inhibition, and empagliflozin strongly lowered BG in Akita (means of 187-237 vs. 517-535 mg/dl in vehicle group; 100-140 mg/dl in WT). Empagliflozin modestly reduced GFR in WT (250 vs. 306 l/min) and completely prevented the diabetes-induced increase in glomerular filtration rate (GFR) (255 vs. 397 l/min). Empagliflozin attenuated increases in kidney weight and urinary albumin/creatinine ratio in Akita in proportion to hyperglycemia. Empagliflozin did not increase urinary glucose/creatinine ratios in Akita, indicating the reduction in filtered glucose balanced the inhibition of glucose reabsorption. Empagliflozin attenuated/prevented the increase in systolic blood pressure, glomerular size, and molecular markers of kidney growth, inflammation, and gluconeogenesis in Akita. We propose that SGLT2 inhibition can lower GFR independent of reducing BG (consistent with the tubular hypothesis of diabetic glomerular hyperfiltration), while attenuation of albuminuria, kidney growth, and inflammation in the early diabetic kidney may mostly be secondary to lower BG. 
 Question: Which protein does empagliflozin inhibit?

Answer: sglt2


Question: Context: It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue-which prompted the FDA to place studies of these compounds on clinical hold in 2010-was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades. 
 Question: What is the target of tanezumab?

Answer:
ngf